JP2023535744A - 片頭痛の治療 - Google Patents

片頭痛の治療 Download PDF

Info

Publication number
JP2023535744A
JP2023535744A JP2023504814A JP2023504814A JP2023535744A JP 2023535744 A JP2023535744 A JP 2023535744A JP 2023504814 A JP2023504814 A JP 2023504814A JP 2023504814 A JP2023504814 A JP 2023504814A JP 2023535744 A JP2023535744 A JP 2023535744A
Authority
JP
Japan
Prior art keywords
migraine
days
atogepant
weeks
baseline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023504814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535744A5 (enExample
Inventor
ジョエル トラグマン
ミシェル フィネガン
Original Assignee
アラーガン ファーマシューティカルズ インターナショナル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80003948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2023535744(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アラーガン ファーマシューティカルズ インターナショナル リミテッド filed Critical アラーガン ファーマシューティカルズ インターナショナル リミテッド
Publication of JP2023535744A publication Critical patent/JP2023535744A/ja
Publication of JP2023535744A5 publication Critical patent/JP2023535744A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
JP2023504814A 2020-07-29 2021-07-29 片頭痛の治療 Pending JP2023535744A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063103353P 2020-07-29 2020-07-29
US63/103,353 2020-07-29
US202063070449P 2020-08-26 2020-08-26
US63/070,449 2020-08-26
US202063087175P 2020-10-02 2020-10-02
US63/087,175 2020-10-02
US202063092211P 2020-10-15 2020-10-15
US63/092,211 2020-10-15
US202063129362P 2020-12-22 2020-12-22
US63/129,362 2020-12-22
US202163201254P 2021-04-20 2021-04-20
US63/201,254 2021-04-20
PCT/US2021/043791 WO2022026767A1 (en) 2020-07-29 2021-07-29 Treatment of migraine

Publications (2)

Publication Number Publication Date
JP2023535744A true JP2023535744A (ja) 2023-08-21
JP2023535744A5 JP2023535744A5 (enExample) 2024-08-05

Family

ID=80003948

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504814A Pending JP2023535744A (ja) 2020-07-29 2021-07-29 片頭痛の治療

Country Status (9)

Country Link
US (2) US12090148B2 (enExample)
EP (1) EP4188375A4 (enExample)
JP (1) JP2023535744A (enExample)
CN (1) CN116390712A (enExample)
AU (1) AU2021319090A1 (enExample)
BR (1) BR112023001615A2 (enExample)
CA (1) CA3190176A1 (enExample)
MX (1) MX2023001071A (enExample)
WO (1) WO2022026767A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10117836B2 (en) 2014-02-05 2018-11-06 Merck Sharp & Dohme Corp. Tablet formulation for CGRP active compounds
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
MX2023001071A (es) 2020-07-29 2023-05-12 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
JP2024533756A (ja) 2021-09-27 2024-09-12 アラガン ファーマスーティカルズ インターナショナル リミテッド アトゲパントを含む片頭痛の併用療法
WO2023055758A1 (en) * 2021-09-29 2023-04-06 Pfizer Ireland Pharmaceuticals Preventative treatment of migraine
CA3244873A1 (en) * 2022-03-09 2023-09-14 Allergan Pharmaceuticals International Limited Preventive treatment for migraines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015166380A (ja) * 2008-06-09 2015-09-24 バイバス・インコーポレイテッドＶｉｖｕｓ， Ｉｎｃ． 体重減少の達成および肥満症の治療のための漸増用量投与計画（ｅｓｃａｌａｔｉｎｇｄｏｓｉｎｇｒｅｇｉｍｅｎ）
WO2019087161A1 (en) * 2017-11-06 2019-05-09 Auckland Uniservices Limited Peptide conjugate cgrp receptor antagonists and methods of preparation and uses thereof
WO2019234710A1 (en) * 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US6103260A (en) 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US20040076668A1 (en) 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
US7288559B2 (en) 2003-03-14 2007-10-30 Merck + Co, Inc. Carboxamide spirohydantoin CGRP receptor antagonists
EP1606286B1 (en) 2003-03-14 2011-05-11 Merck Sharp & Dohme Corp. Benodiazepine spirohydantoin cgrp receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
CA2543458A1 (en) 2003-10-24 2005-05-12 Josef Rettenmaier & Soehne Gmbh & Co., Kg Process for co-spray drying agents with dry silicified mcc
US8003792B2 (en) 2004-09-13 2011-08-23 Merck Sharp & Dohme Corp. Bicyclic anilide spirolactam CGRP receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
DE102004063755A1 (de) 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
EP1861399B1 (en) 2005-03-14 2011-12-14 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
CN101378731B (zh) 2006-02-09 2014-03-05 默沙东公司 Cetp抑制剂的聚合物制剂
WO2007133491A1 (en) 2006-05-09 2007-11-22 Merck & Co., Inc. Substituted spirocyclic cgrp receptor antagonists
CA2689217C (en) 2007-06-05 2016-02-16 Merck & Co., Inc. Carboxamide heterocyclic cgrp receptor antagonists
NZ585347A (en) 2007-10-18 2011-09-30 Boehringer Ingelheim Int Cgrp antagonists
EP2225237A2 (de) 2007-11-22 2010-09-08 Boehringer Ingelheim International GmbH Organische verbindungen
JP2011511792A (ja) 2008-02-05 2011-04-14 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体アンタゴニストのプロドラッグ
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US20150023888A1 (en) 2008-09-05 2015-01-22 Map Pharmaceuticals, Inc. Method of Using Dihydroergotamine for Pre-emptive Treatment of Migraine
WO2010114801A1 (en) 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
US8765763B2 (en) 2009-06-05 2014-07-01 Boehringer Ingelheim International Gmbh Substituted piperazines as CGRP antagonists
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
TWI501968B (zh) 2010-11-12 2015-10-01 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
WO2012064911A1 (en) 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Piperidinone carboxamide indane cgrp receptor antagonists
WO2012087777A1 (en) 2010-12-22 2012-06-28 Merck Sharp & Dohme Corp. Fused heterocyclic indane carboxamide cgrp receptor antagonists
EP2654423B1 (en) 2010-12-22 2016-12-07 Merck Sharp & Dohme Corp. Fused heterocyclic azaindane carboxamide cgrp receptor antagonists
WO2012122279A1 (en) 2011-03-08 2012-09-13 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
WO2012129013A1 (en) 2011-03-18 2012-09-27 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
EP2753640B1 (en) 2011-09-08 2016-03-09 Codexis, Inc. Biocatalysts and methods for the synthesis of substituted lactams
WO2013138418A2 (en) 2012-03-14 2013-09-19 Merck Sharp & Dohme Corp. Process for making cgrp receptor antagonists
WO2013138413A1 (en) 2012-03-14 2013-09-19 Merck Sharp & Dohme Corp. Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts
WO2013162769A1 (en) 2012-04-25 2013-10-31 Centric Research Institute Sensitization composition and method of use
WO2013169563A1 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Pyridine cgrp receptor antagonists
EP2846799B1 (en) 2012-05-09 2017-11-15 Merck Sharp & Dohme Corp. Spirolactam cgrp receptor antagonists
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
US9227972B2 (en) 2012-05-09 2016-01-05 Merck Sharp & Dohme Corp. Aliphatic spirolactam CGRP receptor antagonists
MY196014A (en) 2013-03-15 2023-03-06 Tonix Pharmaceuticals Inc Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride
WO2015038736A2 (en) 2013-09-16 2015-03-19 Merck Sharp & Dohme Corp. Formulations for cgrp receptor antagonists
US10117836B2 (en) 2014-02-05 2018-11-06 Merck Sharp & Dohme Corp. Tablet formulation for CGRP active compounds
EP3102188A4 (en) 2014-02-05 2017-07-12 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
CN106456662A (zh) 2014-02-24 2017-02-22 奥利金制药公司 口服给药的戊聚糖多硫酸盐的组合物及其使用方法
KR20170043597A (ko) 2014-08-22 2017-04-21 클로비스 온콜로지 인코포레이티드 루카파립의 고 용량 강도 정제
CN107427493A (zh) 2015-01-23 2017-12-01 格吕伦塔尔有限公司 用于治疗肝功能受损和/或肾功能受损的受试者的疼痛的Cebranopadol
JP2018532728A (ja) 2015-09-24 2018-11-08 テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー （持続性）外傷後頭痛の予防、治療および低減
US20180092899A1 (en) 2016-09-30 2018-04-05 Merck Sharp & Dohme Corp. Method of treating acute migraine with cgrp-active compound
JP7195262B2 (ja) 2017-03-02 2022-12-23 ベス イスラエル デアコネス メディカル センター インコーポレイティッド カルシトニン遺伝子関連ペプチドを指向する抗体に応答性の頭痛患者の選択方法
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
US20190135927A1 (en) 2017-09-29 2019-05-09 Bhl Patent Holdings, Llc Migraine, headache, chronic pain treatment, and prophylaxis options
US20190374518A1 (en) 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
KR20210116560A (ko) 2019-01-20 2021-09-27 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. 편두통 돌발을 치료하기 위한 cgrp 길항제
US20200383983A1 (en) 2019-04-18 2020-12-10 Allergan Sales, Llc Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo
WO2021005494A1 (en) 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Cgrp antagonists and clostridial derivatives for the treatment of neuropsychiatric and neurological disorders
EP4034156A4 (en) 2019-09-25 2024-01-24 Allergan Pharmaceuticals International Limited COMBINATION THERAPY WITH CGRP ANTAGONISTS
MX2023001071A (es) 2020-07-29 2023-05-12 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
JP2024533756A (ja) 2021-09-27 2024-09-12 アラガン ファーマスーティカルズ インターナショナル リミテッド アトゲパントを含む片頭痛の併用療法
CA3244873A1 (en) 2022-03-09 2023-09-14 Allergan Pharmaceuticals International Limited Preventive treatment for migraines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015166380A (ja) * 2008-06-09 2015-09-24 バイバス・インコーポレイテッドＶｉｖｕｓ， Ｉｎｃ． 体重減少の達成および肥満症の治療のための漸増用量投与計画（ｅｓｃａｌａｔｉｎｇｄｏｓｉｎｇｒｅｇｉｍｅｎ）
WO2019087161A1 (en) * 2017-11-06 2019-05-09 Auckland Uniservices Limited Peptide conjugate cgrp receptor antagonists and methods of preparation and uses thereof
WO2019234710A1 (en) * 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BIGAL ME ET AL.: ""Obesity, migraine, and chronic migraine: possible mechanisms of interaction"", NEUROLOGY，［ONLINE］，［TEXT］, vol. 68, no. 21, JPN6026023897, 2007, ISSN: 0005884344 *
CURRENT PAIN AND HEADACHE REPORTS, vol. 22, no. 5, JPN6025036498, 2018, pages 1 - 6, ISSN: 0005884345 *
ENDOCRINOLOGY, vol. 151, no. 9, JPN7025003937, 2010, pages 4257 - 4269, ISSN: 0005884347 *
ENDOCRINOLOGY, vol. 158, no. 5, JPN7025003936, 2017, pages 1194 - 1206, ISSN: 0005884346 *
HEADACHE, vol. 59, JPN6025036496, 2019, pages 18 - 19, ISSN: 0005884341 *
HEADACHE, vol. Vol. 58 Suppl 3, JPN6025036497, 2018, pages 276 - 290, ISSN: 0005884342 *
NEUROLOGY, vol. 88, no. 19, JPN6026023896, 2017, pages 1795 - 1804, ISSN: 0005884343 *

Also Published As

Publication number Publication date
EP4188375A4 (en) 2024-07-24
BR112023001615A2 (pt) 2023-04-04
US20250186422A1 (en) 2025-06-12
US12090148B2 (en) 2024-09-17
US20220031686A1 (en) 2022-02-03
MX2023001071A (es) 2023-05-12
AU2021319090A1 (en) 2023-03-02
EP4188375A1 (en) 2023-06-07
CA3190176A1 (en) 2022-02-03
CN116390712A (zh) 2023-07-04
WO2022026767A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
US12090148B2 (en) Treatment of migraine
Peters Migraine overview and summary of current and emerging treatment options
US20250177378A1 (en) Treatment of depression
JP7480261B2 (ja) 片頭痛の処置における使用のためのラスミジタンとｃｇｒｐアンタゴニストとの併用療法
Oh et al. Amifampridine phosphate (Firdapse®) is effective and safe in a phase 3 clinical trial in LEMS
Vermersch et al. Tetrahydrocannabinol: cannabidiol oromucosal spray for multiple sclerosis-related resistant spasticity in daily practice
AU2018342072B2 (en) Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations
US20190247333A1 (en) Method of reduction in convulsive seizure frequency
EP3272343A1 (en) Tapentadol for preventing and treating depression and anxiety
EP4489856A2 (en) Preventive treatment of migraine
WO2019067413A1 (en) USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
US20250325532A1 (en) Treatment of migraine
JP2021534197A (ja) 治療抵抗性患者のための抗ｃｇｒｐ抗体
US20090176857A1 (en) Use of Organic Compounds
EP4403181A1 (en) A medicinal product for use in administering in the treatment, control and/or prevention of pain
KR20250085810A (ko) 신경정신 치료에 대한 신체적 의존을 감소시키는 방법
CN118401239A (zh) 用于治疗抑郁症，包括难治性抑郁症的2-氟脱氯氯胺酮
ALSHARABATI et al. AMIFAMPRIDINE PHOSPHATE (FIRDAPSEVR) IS EFFECTIVE AND SAFE IN A PHASE 3 CLINICAL TRIAL IN LEMS
HK40016106A (en) Methods of treating seizure disorders and prader-willi syndrome
NZ750691A (en) Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260615